PDS Biotechnology Corporation
NASDAQ:PDSBBiotechnology
+$0.01 today
- Market cap
- $51.58M
- Beta
- 1.56
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$0.60
Volume 5.25M
Average 1.04M
PDSB Net Income
Bottom-line profit after all expenses, interest, and taxes.
PDS Biotechnology CorporationNASDAQ: PDSB
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$7.35M, compared with -$8.49M a year earlier. Trailing-twelve-month net income was -$33.36M.
Context
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 2 analysts of -$23.04M (+33.2%) for the fiscal year ending Dec 2026, a step up from the +8.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$7.35M+2.8% QoQ
- Last fiscal yearDec 2025
- -$34.5M+8.3% YoY
- LTMMar 2026
- -$33.36M+6.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +13.4% | +25.5% | +12.1 pp |
| 1 year | +8.3% | +33.2% | +24.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (34.5M) USD
- Year-over-year change
- +8.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (34.5M) | +8.3% |
| FY2024 | 2024-12-31 | (37.61M) | +12.4% |
| FY2023 | 2023-12-31 | (42.94M) | -5.1% |
| FY2022 | 2022-12-31 | (40.85M) | -141.5% |
| FY2021 | 2021-12-31 | (16.92M) | — |
Net Income vs competitors
How PDSB compares with its peers on the latest reported figures
- PDSB's LTM Mar 2026 net income of -$33.36M is the 3rd highest of the 6 companies compared; the peer median is -$40.92M.
- Its year-over-year change of +6.0% is the 4th highest of 6, against a peer median of +14.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $11.31M | +127.6% | — | 32.2% | |
| LTM Mar 2026 | -$31.3M | +42.4% | — | 58.5% | |
| LTM Mar 2026 | -$33.36M | +6.0% | — | — | |
| LTM Mar 2026 | -$40.92M | -40.8% | — | — | |
| LTM Mar 2026 | -$41.6M | -2.0% | — | — | |
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | -$58.75M | +14.8% | — | — |
| Peer median (excluding PDSB) | -$40.92M | +14.8% | — | 45.4% | |
Competitors are the stored peer set for PDSB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 57.33K | 59.79K | 0 |
| Gross Profit | 0 | 0 | (57.33K) | (59.79K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 11.25M | 29.43M | 27.76M | 22.57M | 19.03M |
| Selling, General & Admin | 10.18M | 12.24M | 15.28M | 13.7M | 12.52M |
| Operating Expenses | 21.44M | 41.67M | 43.05M | 36.26M | 31.54M |
| Depreciation & Amortization | 5.36K | 86 | 57.33K | 59.79K | 21.84K |
| EBITDA | (21.43M) | (40.74M) | (40.09M) | (33.75M) | (30.3M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (21.44M) | (41.67M) | (43.05M) | (36.32M) | (31.54M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 4.35K | 935.18K | 2.9M | 2.52M | 1.22M |
| Interest Expense | 0 | 1.32M | 4.21M | 4.67M | 5.34M |
| Other Income / Expenses | 4.35K | (381.34K) | (1.3M) | (2.16M) | (4.12M) |
| Income Before Tax | (21.43M) | (42.05M) | (44.35M) | (38.48M) | (35.67M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (4.52M) | (1.2M) | (1.41M) | (869.17K) | (1.17M) |
| Net Income | (16.92M) | (40.85M) | (42.94M) | (37.61M) | (34.5M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.66) | (1.43) | (1.39) | (1.03) | (0.74) |
| EPS (Diluted) | (0.66) | (1.43) | (1.39) | (1.03) | (0.74) |
| Weighted Avg Shares | 25.6M | 28.6M | 30.95M | 36.45M | 46.38M |
| Weighted Avg Shares (Diluted) | 25.6M | 28.6M | 30.95M | 36.45M | 46.38M |
PDS Biotechnology Corporation
NASDAQ:PDSB
Intrinsic Alpha fair value
Locked
Current Price
$0.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.